Trials / Completed
CompletedNCT03995472
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1501 | Administered subcutaneously |
| DRUG | SHR-1316 | Administered intravenously |
Timeline
- Start date
- 2020-02-14
- Primary completion
- 2023-01-12
- Completion
- 2023-01-12
- First posted
- 2019-06-24
- Last updated
- 2023-09-28
Locations
5 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT03995472. Inclusion in this directory is not an endorsement.